Reading the tape
NASDAQ: RARE
Ultragenyx Pharmaceutical Inc.
Healthcare · Biotechnology
Market Cap
$2.44B
52w High
$42.37
52w Low
$18.29
P/E
-4.31
Volume
1.70M
Outstanding Shares
98.32M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -36.17%Revenue (TTM): 20.08%FCF (TTM): -8.71%P/S: 3rd pct
What changed
The stock fell 36.17% over the last year. Revenue grew 20.08% over the trailing twelve months. Operating margin moved from -95.67% to -79.63%. Free cash flow declined 8.71% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -79.63%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally.
CEOEmil D. Kakkis
SectorHealthcare
IndustryBiotechnology
Employees1,294
IPO dateJan 31, 2014
Valuation
Forward P/E—
EV/EBITDA-6.22
Enterprise value$3.11B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth25.55%
Gross margin83.85%▼2.90%vs FY2024
Operating margin-79.63%▲16.91%vs FY2024
ROE718.75%▲422.38%vs FY2024
Analyst consensus
RatingBuy
Target price$51.50▲107.58%
27
Buy
5
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$1.50 · Revenue est $158.38M
View